OrganoTherapeutics SARL-S

We use of a proprietary human brain organoids, for the discovery and development of drug candidates, for treating different Parkinson’s patients subgroups.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Luxembourg
  • Currency EUR
  • Founded July 2019
  • Employees 2
  • Incorporation Type S-corp
  • Website organo-therapeutics.com

Company Summary

Pillars of OT:
1) Our proprietary model, the brain organoids, which recapitulate the brain area affected by Parkinson’s disease (PD).
2) Accessibility to a unique stratified library of patient derived material.
3) Development of drug candidates through libraries of chemically defined molecules and of natural fractions extracted from marine and floral organisms.
4) Strong R&D link to the LCSB to advance models to mirror faithfully the human brain.

Team

  • Javier Jarazo
    CSO

    Dr. Jarazo is the CSO in charge of the 3D model optimization and the phenotyping screening. Besides training and reviewing the production of the staff, he encourages and leads further customizations of the service.

  • Jens Schwamborn
    CEO

    Prof. Dr. Schwamborn is the CEO, responsible for the development and the projects OT engages. Through the University Luxembourg, he will facilitate a continuous flow of innovation from academic research to commercialization.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free